SCHEMBL2391712

SCHEMBL2391712

O=C(O)Cc1ccc(Cl)cc1Sc1ccc(Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.51
HPGD P15428 1/20 0.51
CYP2C19 P33261 1/20 0.51
RHEB Q15382 5/20 0.50
PTGDR2 Q9Y5Y4 3/20 0.50
KEAP1 Q14145 1/20 0.48
NFE2L2 Q16236 1/20 0.48
AGBL2 Q5U5Z8 1/20 0.47
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45
MMP12 P39900 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
MAPK1 P28482 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
POLB P06746 1/20 0.42
AKR1B1 P15121 1/20 0.42
LMNA P02545 1/20 0.42
CXCL8 P10145 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11759221 0.91 AGBL2 (0.55) CYP2C9HPGDCYP2C19RHEBPTGDR2
SCHEMBL4733549 0.88 AGBL2 (0.59) CYP2C9HPGDCYP2C19RHEBPTGDR2
SCHEMBL11761893 0.84 MMP2 (0.60) CYP2C9HPGDCYP2C19AGBL2MMP2
SCHEMBL27971821 0.84 CYP2C9 (0.72) CYP2C9HPGDCYP2C19RHEBAGBL2
SCHEMBL11759778 0.83 SLC6A9 (0.48) CYP2C9HPGDCYP2C19RHEBKEAP1
SCHEMBL11453265 0.82 AGBL2 (0.50) CYP2C9HPGDCYP2C19RHEBPTGDR2
SCHEMBL6660771 0.80 MMP9 (0.44) CYP2C9HPGDCYP2C19AGBL2MMP2
SCHEMBL29070042 0.80 KEAP1 (0.46) CYP2C9PTGDR2KEAP1NFE2L2AKR1B1
SCHEMBL11477833 0.80 AGBL2 (0.50) CYP2C9HPGDCYP2C19RHEBPTGDR2
SCHEMBL11756903 0.79 AGBL2 (0.66) CYP2C9HPGDCYP2C19RHEBPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases ASTRAZENECA AB (SE) 2008-05-15 US claimed
EP-1765768-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES AstraZeneca AB (SE) 2007-03-28 EP claimed
WO-2006005909-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2006-01-19 WO claimed
US-8022248-B2 3-[2-(3-Cyanophenoxy)-4-(trifluoromethyl)phenyl]propanoic acid;prostaglandin D2 inhibitor, orphan receptor CRTH2 antagonist; antiinflammatory, analgesic, antipyretic; respiratory system disorders: asthma and rhinitis; coupling amino/thio-phenyl derivatives with ester followed by hydrolysis to acid ASTRAZENECA AB (SE) 2011-09-20 US disclosed
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases ASTRAZENECA AB (SE) 2008-05-15 US disclosed
EP-1765768-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES AstraZeneca AB (SE) 2007-03-28 EP disclosed
WO-2006005909-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases HRH2, HRH1, HRH4 CYP2C9 784/4885HPGD 700/4885CYP2C19 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.